The Sevillian biotech Universal DX captures 14 million for its colon cancer test

Sevilla

Updated:14/01/2021 07:24h

save

The funding round opened by the Sevillian biotechnology Universal DX (UDX) It has exceeded all forecasts, since the company founded by Juan Martínez Barea has raised 14 million euros in 2020, four million more than initially planned. The round, covered by the company’s own shareholders, will allow the company to continue with its clinical trials, complete the colon cancer detection test this year with the intention of launching it on the market in 2022 with a reliability of more than 90% .

Created in 2012 in Seville, Universal DX has already raised 35 million euros: 30 million among private investors and 5 million euros in the public sector, since it raised funds

.

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.